Considering that an acidic tumor microenvironment crucially impairs immune effector cell activation and therefore anti-tumor immune responses [28], we hypothesized that the efficacy of EGFR-targeting antibody-based therapy can be increased by metabolic reprogramming of the tumor itself. This evidence concerns the gene EGFR and neoplasm.